{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:47:52Z","timestamp":1788814072573,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06722-2","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:06:14Z","timestamp":1763129174000},"page":"6435-6437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful fatherhood of males with tyrosine kinase inhibitor-resistant chronic myeloid leukemia taking olverembatinib"],"prefix":"10.1007","volume":"104","author":[{"given":"Lu","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"1","key":"6722_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","volume":"15","author":"Q Jiang","year":"2022","unstructured":"Jiang Q et al (2022) Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol 15(1):113","journal-title":"J Hematol Oncol"},{"issue":"8","key":"6722_CR2","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF et al (2025) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia 39(8):1797\u20131813","journal-title":"Leukemia"},{"issue":"5","key":"6722_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/leu.2015.36","volume":"29","author":"L Kalmanti","year":"2015","unstructured":"Kalmanti L et al (2015) Safety and efficacy of imatinib in CML over a\u00a0period of 10 years: data from the randomized CML-study IV. Leukemia 29(5):1123\u20131132","journal-title":"Leukemia"},{"issue":"14","key":"6722_CR4","doi-asserted-by":"publisher","first-page":"e35953","DOI":"10.1002\/cncr.35953","volume":"131","author":"H Kantarjian","year":"2025","unstructured":"Kantarjian H et al (2025) Management of chronic myeloid leukemia in 2025. Cancer 131(14):e35953","journal-title":"Cancer"},{"issue":"18","key":"6722_CR5","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1182\/blood.2024024761","volume":"144","author":"X Zhang","year":"2024","unstructured":"Zhang X et al (2024) A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Blood 144(18):1951\u20131961","journal-title":"Blood"},{"issue":"4","key":"6722_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/1078155213500686","volume":"20","author":"VS Ghalaut","year":"2014","unstructured":"Ghalaut VS et al (2014) Effect of Imatinib on male reproductive hormones in BCR-ABL positive CML patients: a preliminary report. J Oncol Pharm Pract 20(4):243\u2013248","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"6722_CR7","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/14740338.2021.1893299","volume":"20","author":"E Lorenzi","year":"2021","unstructured":"Lorenzi E et al (2021) Risks of molecular targeted therapies to fertility and safety during pregnancy: a review of current knowledge and future needs. Expert Opin Drug Saf 20(5):503\u2013521","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"6722_CR8","first-page":"e33407","volume":"15","author":"M Abu-Tineh","year":"2023","unstructured":"Abu-Tineh M et al (2023) The impact of tyrosine kinase inhibitors on fatherhood in patients with chronic myeloid leukemia: A Mixed-Method study. Cureus 15(1):e33407","journal-title":"Cureus"},{"key":"6722_CR9","doi-asserted-by":"crossref","unstructured":"Yu L et al (2024) Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib therapy. Cancer","DOI":"10.1007\/s00277-025-06722-2"},{"key":"6722_CR10","doi-asserted-by":"crossref","unstructured":"Zhang X et al (2025) Optimizing olverembatinib dose in chronic phase chronic myeloid leukemia. Haematologica","DOI":"10.3324\/haematol.2024.287116"},{"issue":"5","key":"6722_CR11","doi-asserted-by":"publisher","first-page":"102131","DOI":"10.1016\/j.clgc.2024.102131","volume":"22","author":"M Marino","year":"2024","unstructured":"Marino M et al (2024) New insights of target therapy: effects of tyrosine kinase inhibitors on male gonadal function: A systematic review. Clin Genitourin Cancer 22(5):102131","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"6722_CR12","doi-asserted-by":"publisher","first-page":"e0243045","DOI":"10.1371\/journal.pone.0243045","volume":"15","author":"Z Szak\u00e1cs","year":"2020","unstructured":"Szak\u00e1cs Z et al (2020) Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review. PLoS ONE 15(12):e0243045","journal-title":"PLoS ONE"},{"key":"6722_CR13","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1182\/blood-2024-200186","volume":"144","author":"E Abruzzese","year":"2024","unstructured":"Abruzzese E et al (2024) The impact of Ponatinib on pregnancy outcomes. Blood 144:2435\u20132436","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06722-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06722-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06722-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:15Z","timestamp":1767485715000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06722-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":13,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6722"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06722-2","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all the individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participants consented to the submission of the case report to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}